Cancers · 2022 · 22 citations · 85 references
MedicineMolecular BiologyOncologyCancer GeneticsMetastasisMolecular OncologyCancer BiomarkersCancer Molecular DiagnosticsCancer Molecular PathologyMolecular Tumor ProfilingOncogene MutationsOncogenic Signaling PathwaysBreast Cancer PrognosisCancer Mutation AnalysisKit SignalingMissense MutationsOncogenic Receptor Tyrosine Kinase MutationsProto-oncogene MutationTumor Mutation AnalysisTumor Profiling
To investigate a potential role for galectins as biomarkers that enable diagnosis or prognostication of breast or non-small cell lung cancer, the serum levels of galectins -1, -3, -7, -8, and -9 of cancer patients determined by ELISA assays were compared to the mutation status of 50 known cancer-critical genes, which were determined using multiplex PCR in tumors of the same patients. Mutations in the KIT proto-oncogene, which codes for the c-Kit protein, a receptor tyrosine kinase, correlated with higher levels of galectins -1, -3, -8, and -9 in breast cancer patients and galectin-1 in non-small cell lung cancer patients. Mutations in the KIT gene were more likely found in brain metastases from both of these primary cancers. The most common KIT mutation in our panel was p.M541L, a missense mutation in the transmembrane domain of the c-Kit protein. These results demonstrate an association between KIT oncogenic signaling and elevated serum galectins in patients with metastatic disease. Changes in protein trafficking and the glycocalyx composition of cancer cells may explain the observed alterations in galectin expression. This study can be useful for the targeted selection of receptor tyrosine kinase and galectin inhibitor anti-cancer treatments.
85
Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2021 · 17.4K citations · Full text
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Francisco Sánchez-Vega, Marco Mina, Joshua Armenia et al. · Cell · 2018 · 3.4K citations · Full text
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2016 · 3.3K citations · Full text
Medicine, Oncology, Pharmacology +16